Company news

Insulet Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

May 8, 2025

Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency¹)

May 7, 2025

Insulet Appoints Ashley McEvoy President and CEO

April 27, 2025

Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

April 7, 2025

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

April 2, 2025

Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

March 18, 2025

Insulet Expands Omnipod® 5 to Four More International Markets

March 17, 2025

Insulet Announces Proposed Financing Transactions

March 17, 2025

Insulet Announces Pricing of Senior Notes Due 2033

March 17, 2025

From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes

March 17, 2025

Insulet to Host Investor Day on June 5, 2025

March 10, 2025

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

February 19, 2025

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

January 12, 2025

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

January 9, 2025

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

December 3, 2024

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

November 19, 2024

Insulet to Present at Upcoming Investor Conferences

November 14, 2024

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency¹)

November 6, 2024

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

October 31, 2024

Omnipod® 5 App for iPhone® Now Fully Available in the United States

October 28, 2024

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

September 29, 2024

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

August 25, 2024

Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia

August 13, 2024

Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year

August 7, 2024

Insulet Reports Preliminary Second Quarter 2024 Revenue Results

July 25, 2024

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

July 24, 2024

Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

July 7, 2024

Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

June 20, 2024

Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

June 19, 2024

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

June 19, 2024

Insulet to Present at the Jefferies Global Healthcare Conference

May 27, 2024

Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year

May 8, 2024

Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth

May 6, 2024

Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

April 2, 2024

Insulet Appoints Ana Maria Chadwick as Chief Financial Officer

March 19, 2024

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

March 7, 2024

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

March 4, 2024

Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)

February 21, 2024

Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference

February 12, 2024

Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor

February 6, 2024

Imperative Care Announces Four Senior Leadership Appointments

January 28, 2024

Insulet Announces Changes to Board of Directors with Retirements and New Appointments

January 17, 2024

Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

January 10, 2024

Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency¹)

November 1, 2023

Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November

October 31, 2023

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

October 22, 2023

Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5

October 1, 2023

Insulet to Announce Third Quarter 2023 Financial Results on November 2, 2023

September 27, 2023

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany

August 27, 2023

Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency¹)

August 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.